Corbus Pharmaceuticals Holdings Inc. (CRBP) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $4.22 (0.00% 1D, market cap $81.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CRBP ranks #352 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRBP carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RLYB (Rallybio Corporation) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $83.0M) and INO (Inovio Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $79.8M). Among the 5-stock peer group, CRBP leads on earnings multiple (N/A) while CRBP leads on capital efficiency (-35.0% ROIC).
Per CRBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001595097), Corbus Pharmaceuticals Holdings Inc. generated $0 in revenue, -$78.5M in net income, and -$64.5M in free cash flow against $168.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 25.6 (OVERSOLD (<32))
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While CRBP currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.17) and Max Pain ($4.43) forces dealer call-delta covering toward $13.52.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Corbus Pharmaceuticals Holdings Inc. (CRBP) slipped 0.00% to $4.22, trading at 4% of its 52-week range ($3.87 – $12.88). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
MarketWatch report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
MarketWatch report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data f
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data from the CRB-913 Canyon-1 Phase 1B study will be
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRBP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRBP. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Corbus Pharmaceuticals Holdings Inc. (CRBP) ranks #352 by composite RQD confidence (47/100, grade D) and #684 by equity capitalization ($81.6M). Within this direct 5-issuer industry benchmark cohort, CRBP leads on earnings valuation at N/A trailing P/E, while CRBP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CRBP currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CRBP
ACTIVE
Corbus Pharmaceuticals Holdings Inc. | D | 47/100 | — | — | -35.0% | 0.00% | $81.6M | Benchmark Subject |
| RLYB Rallybio Corporation | D- | 37/100 | — | — | -35.0% | +0.84% | $83.0M | /rlyb-vs-crbp → |
| INO Inovio Pharmaceuticals Inc. | E | 34/100 | — | — | -35.0% | -21.95% | $79.8M | /ino-vs-crbp → |
| QUCY Quantum Cyber N.V. | D- | 35/100 | — | 72.6% | -35.0% | -7.69% | $79.4M | /qucy-vs-crbp → |
| SDEV Stablecoin Development Corporation | D- | 42/100 | — | — | -35.0% | -6.48% | $79.0M | /sdev-vs-crbp → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Corbus Pharmaceuticals Holdings Inc. (CRBP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$78.5M, operating cash flow of -$64.5M, and free cash flow of -$64.5M (-54.3% YoY). On the balance sheet, CRBP closed FY2025 with $168.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$78.5M | -$64.5M | -$64.5M | $168.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$40.2M | -$41.8M | -$41.8M | $155.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$44.6M | -$36.1M | -$36.1M | — | — |
As of 2026-11-02, Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $4.22 (0.00% 1D, market cap $81.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CRBP ranks #352 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRBP carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RLYB (Rallybio Corporation) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $83.0M) and INO (Inovio Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $79.8M). Among the 5-stock peer group, CRBP leads on earnings multiple (N/A) while CRBP leads on capital efficiency (-35.0% ROIC).
Per CRBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001595097), Corbus Pharmaceuticals Holdings Inc. generated $0 in revenue, -$78.5M in net income, and -$64.5M in free cash flow against $168.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CRBP last traded at $4.22 (0.00% on volume of 2,317,276 shares), positioning the stock -41.14% below its 50-day simple moving average ($7.17) and -51.04% below its 200-day simple moving average ($8.62). Across its 52-week range of $3.87 to $12.88, CRBP sits at the 3.9% percentile with a 14-day RSI of 25.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.69 to $4.75).
Why CRBP Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, CRBP scores 47 / 100, letter grade D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:
Taken together, the low pillar scores for cash generation, insider conviction, and forensic strength drive the D grade. For a prospective investor, the upside case rests mainly on the fact that the stock trades well below its 52-week high and that the macro pillar is comparatively neutral. The valuation tradeoff is that with no positive earnings or free cash flow in the source data, traditional earnings-based valuation cannot be anchored. The downside risk is that the rating itself signals a distribution warning. This is educational analysis, not personalized financial advice.
Corbus Pharmaceuticals Holdings Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, its market capitalization is $0.1B. Per the SEC financials, reported revenue is $0.0M for FY 2025, FY 2024, and FY 2023, so the source data does not show a revenue-generating customer base. Not available in source data: a product list, customer identities, or the company's monetization model beyond the absence of reported revenue.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-85.3M | $-78.5M | N/A | $-64.5M | $28.5M | N/A |
| FY 2024 | $0.0M | $-48.7M | $-40.2M | N/A | $-41.8M | $17.2M | N/A |
| FY 2023 | $0.0M | $-45.1M | $-44.6M | N/A | $-36.1M | N/A | N/A |
Per the SEC financials, operating losses widened from $-45.1M in FY 2023 to $-85.3M in FY 2025, and net losses followed the same direction. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Reported cash rose to $28.5M in FY 2025, but Not available in source data: debt levels for the reported periods.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Corbus Pharmaceuticals Holdings Inc. (CRBP) • Click "Debate This Headline" to argue it in the Roar Pit below
MarketWatch report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
MarketWatch report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data f
Welcome to the CRBP (Corbus Pharmaceuticals Holdings Inc.) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on CRBP, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Corbus Pharmaceuticals Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on CRBP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $4.22 (52-wk range $3.87 - $12.88), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).